VACCINE ADJUVANT MARKET ANALYSIS

Vaccine Adjuvant Market, By Type (Mineral Salt-based Adjuvant, Tensoactive Adjuvants, Adjuvant Emulsions, Liposome Adjuvants, Carbohydrate Adjuvants, Bacteria-derived Adjuvants, Virus-like Particles (VLP), and Other Types), By Usage (Active Immunostimulants, Carriers, and Vehicle Adjuvants), By Disease Type (Infectious Disease and Cancer), By Application (Research Applications and Commercial Applications), and By Geography (North America, Europe, Asia Pacific, Middle East and Africa, and Rest of World)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Jan 2023
Code : CMI1731
Pages :169
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Global Vaccine Adjuvant Market: Key Companies Insights

The global Vaccine Adjuvant Market is highly competitive. This is attributed to the increase in use of vaccine adjuvants to treat variety of diseases, as a result, players in the market are focusing on launching novel products in the market.

Some of the key players in the global vaccine adjuvant market are Thermo Fisher Scientific Inc., Air Liquide (Seppic), Pacific GeneTech Limited, OZ Biosciences, Novavax Inc., Merck & Co. Inc., InvivoGen, GlaxoSmithKline PLC, Dynavax Technologies Corporation, CSL Limited, Croda International PLC, Vertellus, Aphios Corporation, Agenus Inc., Adjuvatis, and Associated British Foods PLC (SPI Pharma Inc.), among others.